Status:
UNKNOWN
Clonidine Versus Tranexamic Acid in Reduction of Blood Loss
Lead Sponsor:
Uwakwe Emmanuel Chijioke
Conditions:
Blood Loss
Eligibility:
FEMALE
18-45 years
Phase:
PHASE1
Brief Summary
Tranexamic acid is an antifibrinolytics agent that has been widely used in the reduction of blood loss at surgeries. Oral clonidine is an alpha-2 adrenergic agonist that has been used in various surge...
Detailed Description
SUMMARY Background: Primary postpartum haemorrhage is a leading cause of maternal mortality and morbidity. Prevention of excessive blood loss at caesarean section is of utmost concern to the obstetric...
Eligibility Criteria
Inclusion
- \- Participants for the study include consenting parturients with singleton pregnancy at 37-42 weeks gestational age,admitted for elective caesarean section.
Exclusion
- Prior history of thromboembolism or bleeding disorder
- Renal disease
- Liver disease
- Antepartum Hemorrhage
- Intrauterine Growth restricted fetuses
- Patient refusal
Key Trial Info
Start Date :
January 3 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 3 2022
Estimated Enrollment :
112 Patients enrolled
Trial Details
Trial ID
NCT05371574
Start Date
January 3 2022
End Date
August 3 2022
Last Update
May 12 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
AEFUTHA
Abakaliki, Ebonyi State, Nigeria, 234